本文源自智通财经网 近年来，全球胰高血糖素样肽-1受体激动剂(GLP-1)类药物市场持续扩容，2025年仅一季度，其相关领 域的全球交易规模便达到130.24亿美元，接近上年全年总额。据了解，派格生物医药目前拥有六款候选 药物组成的多元化研发管线，其中三款正在进行临床试验，一款已获得IND批准。其中，该公司的核心 产品PB-119为自主开发、接近商业化阶段的长效胰高血糖素样肽1(GLP-1，一种降低血糖水平的肽类激 素)受体激动剂。 智通财经获悉，派格生物医药-B(02565)大涨超40%，截至发稿，涨37.83%，报33.83港元，成交额 2335.58万港元，最新市值突破128.52亿港元。 消息面上，减肥药概念银诺医药-B(02591)今早首挂上市大幅高开285%，市值超328亿港元。此前招股期 间，银诺医药获超额认购5340倍，荣登今年新股"超购王"第二位，而这反映的正是资本市场对于GLP-1 类药物赛道以及内分泌疾病治疗市场的关注。值得一提的是，近期派格生物医药同样走出一波股价上涨 行情，当前最新市值港元，较同行业银诺医药的市值还有很大空间，凸显市场对于该公司长期价值的认 可。 ...

Group 1 - The core viewpoint of the article highlights the significant stock price increase of Paig BioPharma-B (02565), which surged over 40%, reaching a price of 33.83 HKD and a market capitalization exceeding 12.852 billion HKD [1] - The recent listing of Silver Novo Pharma-B (02591) saw a remarkable opening increase of 285%, with a market capitalization surpassing 32.8 billion HKD, indicating strong market interest in GLP-1 drug candidates and endocrine disease treatments [1] - The global market for GLP-1 receptor agonists has been expanding, with the transaction volume in the first quarter of 2025 reaching 13.024 billion USD, nearly matching the total for the previous year [1] Group 2 - Paig BioPharma currently has a diversified pipeline consisting of six candidate drugs, with three in clinical trials and one having received IND approval [1] - The company's core product, PB-119, is a long-acting GLP-1 receptor agonist that is self-developed and nearing commercialization, aimed at lowering blood sugar levels [1]

Group 1 - The core viewpoint of the article highlights the significant stock price increase of Pagoda Biopharma-B (02565), which surged over 40%, reflecting strong market interest in GLP-1 drug candidates and the broader endocrine disease treatment market [1] - The recent IPO of Silverno Pharmaceuticals-B (02591) opened with a remarkable 285% increase, achieving a market capitalization exceeding 32.8 billion HKD, indicating high investor demand and interest in the GLP-1 drug sector [1] - The global market for GLP-1 receptor agonists has been expanding, with the transaction volume reaching 13.024 billion USD in the first quarter of 2025, nearly matching the total for the previous year [1] Group 2 - Pagoda Biopharma currently has a diversified pipeline of six candidate drugs, with three in clinical trials and one having received IND approval, showcasing its commitment to innovation in the GLP-1 space [1] - The company's core product, PB-119, is a long-acting GLP-1 receptor agonist that is nearing commercialization, positioning the company for potential growth in the diabetes treatment market [1] - The market recognizes the long-term value of Pagoda Biopharma, as its current market capitalization still has significant room for growth compared to its industry peer, Silverno Pharmaceuticals [1]

Industry Overview - The global GLP-1 receptor agonist market is expanding rapidly, with sales expected to exceed $50 billion in 2024, and the global transaction scale in the first quarter of 2025 reaching $13.024 billion, nearly matching the total for the previous year, indicating a significant increase in the weight loss drug market [1] Company Focus - Silverno Pharmaceuticals-B (02591), focused on GLP-1 drug development, recently saw its IPO surge over 270%, achieving a market capitalization of over HKD 32.4 billion, reflecting strong market interest in the GLP-1 sector and endocrine disease treatment [2] - Another notable player, PegBio Pharmaceuticals-B (02565), has also experienced a stock price increase, with a current market capitalization of HKD 9.3 billion, indicating substantial room for growth compared to Silverno Pharmaceuticals-B [2] - PegBio Pharmaceuticals specializes in innovative therapies for chronic diseases and has developed a proprietary high-efficiency target screening and molecular modification platform (HECTOR), which includes a drug molecule design platform featuring PEG technology to enhance drug stability and reduce research costs [2] Product Pipeline - PegBio Pharmaceuticals has developed a core product and five candidate drugs targeting common chronic and metabolic diseases such as type 2 diabetes, obesity, and non-alcoholic fatty liver disease [3] - The core product, Weipinaide, is highlighted as a significant innovation in PegBio's pipeline, supported by national initiatives for major new drug creation [5] Market Positioning - Weipinaide is recognized as a first-line treatment for type 2 diabetes (T2DM) due to its multiple benefits, including rapid onset of action and sustained efficacy over long-term treatment, making it suitable for lifelong management of diabetes [6] - Clinical results show that Weipinaide significantly reduces HbA1c levels within four weeks and maintains efficacy without rebound effects over 52 weeks, aligning with the treatment needs of diabetes patients [6] - Compared to competitors, Weipinaide offers multiple clinical benefits, including weight loss for high BMI patients, comprehensive heart and kidney protection, and improved beta-cell function and insulin sensitivity [7] Strategic Market Insights - China, as the second-largest pharmaceutical market, is projected to have 164 million diabetes patients and 200 to 250 million overweight individuals by 2030, making it a key strategic area for pharmaceutical companies [8] - PegBio Pharmaceuticals is positioned to reshape the domestic T2DM treatment market through its innovative capabilities and the core product Weipinaide, unlocking its intrinsic value as the market potential continues to grow [8]

派格生物医药-B(02565.HK)公告，公司将于2025年8月26日(星期二)举行董事会会议，藉以(其中包括)考 虑及批准集团截至2025年6月30日止6个月的中期业绩及其刊发，以及处理任何其他事项。 ...

PegBio Co., Ltd. 派格生物醫藥（杭州）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2565） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 董事會會議日期 派格生物醫藥（杭州）股份有限公司（「本公司」，連同其附屬公司統稱「本集團」） 董事（「董事」）會（「董事會」）謹此宣佈，本公司將於2025年8月26日（星期二）舉 行董事會會議，藉以（其中包括）考慮及批准本集團截至2025年6月30日止六個月 的中期業績及其刊發，以及處理任何其他事項。 中國杭州，2025年8月14日 於本公告日期，本公司董事會包括：(i)執行董事Michael Min XU博士及王小軍女 士；(ii)非執行董事Xiangjun ZHOU博士、徐宇虹博士、翟婷女士及李宏凱先生； 以及(iii)獨立非執行董事Jiancun ZHANG博士、陳秧秧博士及范新鵬女士。 Michael Min XU 承董事會命 派格生物醫藥（杭州）股份有限公司 董 ...

Company Summary - Pag Biopharma-B (02565) saw its stock price increase by over 15%, reaching a new high of 24.14 HKD during trading, and currently trading at 23.24 HKD with a transaction volume of 20.32 million HKD [1] - The company’s drug PB-119, aimed at treating Type 2 Diabetes Mellitus (T2DM), is expected to receive NDA approval in 2025 and will be commercialized in China [1] - PB-119 has also initiated Phase Ib/IIa clinical trials for obesity treatment, with participant recruitment expected to be completed by June 2024 [1] - Pag Biopharma is exploring the potential of PB-119 in combination therapies to expand its range of indications [1] Industry Insights - The weight loss drug market has gained significant traction, particularly with GLP-1 receptor agonists like semaglutide becoming popular globally [1] - Analysts from CITIC Securities indicate that weight loss consumption has characteristics of self-indulgent spending, which can lead to the emergence of blockbuster products [1] - With overseas companies like Novo Nordisk and Eli Lilly exceeding performance expectations and accelerated domestic R&D progress, the trend in the weight loss drug industry is expected to become clearer [1] - The domestic weight loss drug market is anticipated to grow rapidly as more related drugs receive approval [1]

Group 1 - The core viewpoint of the article highlights the significant stock price increase of Pagoda Biopharmaceuticals-B (02565), which rose over 15% and reached a new high of 24.14 HKD during trading [1] - As per Pagoda Biopharmaceuticals-B's prospectus, the drug PB-119, intended for treating Type 2 Diabetes Mellitus (T2DM), is expected to receive NDA approval by 2025 and will be commercialized in China [1] - PB-119 has also initiated Phase Ib/IIa clinical trials for obesity treatment, with participant recruitment expected to be completed by June 2024 [1] Group 2 - The company aims to explore the therapeutic potential of PB-119 in combination therapies, thereby expanding its range of indications beyond T2DM and obesity [1] - The obesity medication market has gained traction, particularly with GLP-1 receptor agonists like semaglutide becoming popular globally [1] - Analysts from CITIC Securities suggest that the obesity medication market is likely to grow rapidly in China, driven by the success of overseas companies like Novo Nordisk and Eli Lilly, as well as accelerated domestic R&D progress [1]

Company Overview - Pag BioPharma-B (02565) saw its stock price increase by over 15%, reaching a new high of 24.14 HKD during trading, and currently trading at 23.24 HKD with a transaction volume of 20.32 million HKD [1] Product Development - The company’s drug PB-119, intended for the treatment of Type 2 Diabetes Mellitus (T2DM), is expected to receive NDA approval by 2025 and will be commercialized in China [1] - PB-119 has also initiated Phase Ib/IIa clinical trials for obesity treatment, with participant recruitment expected to be completed by June 2024 [1] - Pag BioPharma is exploring the potential of PB-119 in combination therapies to further expand its indications [1] Industry Trends - The weight loss drug market has gained significant traction, particularly with GLP-1 receptor agonists like semaglutide becoming popular globally [1] - Analysts from CITIC Securities indicate that weight loss consumption exhibits characteristics of self-indulgent spending, which can lead to the emergence of blockbuster products [1] - With overseas companies like Novo Nordisk and Eli Lilly exceeding performance expectations and accelerated domestic R&D progress, the industry trend for weight loss drugs is expected to become clearer [1] - The domestic weight loss drug market is anticipated to grow rapidly as more related drugs receive approval [1]

公司名稱: 派格生物醫藥 ( 杭州 ) 股份有限公司 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02565 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 279,164,339 | RMB | | 1 RMB | | 279,164,339 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 279,164,339 | RMB | | 1 RMB | | 279,164,339 | | 2. 股份分類 | 普通股 ...